Month: July 2021

Nanterre (France), July 26, 2021   Availability of the Financial report for the first half of 2021   Faurecia announces today that its Financial report for the first half of 2021 is available to the public and was filed with the French Autorité des marchés financiers.   It is available for consultation on the corporate website of the Company:   https://www.faurecia.com/en/investors/regulated-information/universal-registration-documents-half-year-results  Press contact Analysts/Investors contactEric Fohlen-Weill Director of Corporate Communication Tel.: +33 (0)1 72 36 72 58 eric.fohlen-weill@faurecia.com Marc Maillet Director of Investor Relations Tel.: +33 (0)1 72 36 75 70 marc.maillet@faurecia.com  About Faurecia Founded in 1997, Faurecia has grown to become a major player in the global automotive industry. With 266...

Lantern will reacquire global rights to Irofulven and assume full authority to manage and guide future clinical and commercial development of the programPress release Hørsholm, Denmark and Dallas, TX, U.S.A. (July 26, 2021) – Allarity Therapeutics A/S (“Allarity”) and Lantern Pharma Inc. (“Lantern”) today announced that they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven (“LP-100”) and assume full authority to manage and guide future clinical development and commercialization. Irofulven is a well-studied small molecule that causes bulky single strand DNA adducts that cause DNA damage in cancer cells, which can only be repaired by the transcription coupled nucleotide excision repair (TC-NER) pathway. This DNA modification stalls RNA polymerase II leading to transcription and cell...

Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, July 26, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) is planning to file a New Drug Application (NDA) for the marketing authorization of the antifungal isavuconazole (Cresemba®) in Japan, based on the positive results of the recently completed phase 3 study in deep-seated mycoses. Asahi Kasei Pharma plans to publish topline results of the study at a later point in time. The phase 3, multi-center, open-label study enrolled 103 patients and was assessing the safety and efficacy of intravenously or orally administered isavuconazole for the treatment of adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis, chronic pulmonary aspergillosis (CPA), mucormycosis...

Sustained operational and financial performance in a still active competitive environmentMobile postpaid customer base +3.4% yoy / Cable customer base +27.0% yoy Q2 Revenues +7.5% yoy / Q2 Retail service revenues +4.9% yoy Q2 EBITDAaL +5.9% yoy (H1’21: +8.8%)Q2 Operational HighlightsCommercial performance remains positive amid an active competitive environment, and lower impact of Covid-19 measures in comparison to last year. Cable customer base increased by 17k during Q2 to 366k customers (+27% yoy). As a consequence the number of convergent mobile postpaid customers increased as well. 17k new mobile postpaid additions bringing total subscribers to 2.7m (+3.4% yoy) demonstrating the success of the Go portfolio. B2C convergent ARPO decreased by 2.7% yoy to €73.6, as a result of the discounts provided on mobile tariff plans in...

July 26, 2021 Second-quarter highlightsGroup sales increased to EUR 4.2 billion, with 9% comparable sales growth Comparable order intake decreased 15%, with strong double-digit growth in the Diagnosis & Treatment businesses and a decline in the Connected Care businesses on the back of COVID-19-related 167% growth in Q2 2020 Income from continuing operations decreased to EUR 65 million due to a EUR 250 million provision related to field actions to address a component quality issue. Income from continuing operations was EUR 195 million in Q2 2020. Adjusted EBITA increased to EUR 532 million, or 12.6% of sales, compared to EUR 390 million, or 9.8% of sales, in Q2 2020 Operating cash flow amounted to EUR 332 million, compared to EUR 446 million in Q2 2020 Free cash flow was EUR 167 million, compared to EUR 212 million in Q2 2020Frans...

Rapid reduction and sustained normalization of heparan sulfate in CSF demonstrated robust and durable CNS activity with intravenous administration, and enhanced peripheral activity with reductions in urine and serum heparan sulfate after switching from standard-of-care idursulfaseGlobal Impression of Change scales data suggested clinical improvement in overall MPS II symptoms, cognitive abilities, behavior, and physical abilitiesExploratory biomarker data demonstrated reductions in CSF lysosomal lipid biomarkers that are consistent with improved lysosomal function; and high variability in exploratory biomarker Nf-L was observed pre- and post-treatmentSafety profile with up to 43 weeks of dosing was consistent with standard of care enzyme replacement therapy with infusion-related reactions being the most frequently observed adverse...

In week 29 Kvika banki hf. („Kvika“ or „the bank“) purchased 10,000,000 of its own shares at the purchase price 238,600,000 ISK. See further details below:Date Time No. of shares purchased Share price (rate) Purchase price19.7.2021 09:39:51 1,000,000 24.400 24,400,00019.7.2021 10:20:45 1,000,000 24.400 24,400,00020.7.2021 09:59:32 1,000,000 24.000 24,000,00020.7.2021 10:25:01 1,000,000 24.000 24,000,00021.7.2021 09:41:29 1,000,000 23.800 23,800,00021.7.2021 10:18:49 1,000,000 23.800 23,800,00022.7.2021 09:47:52 1,000,000 23.700 23,700,00022.7.2021 11:30:44 1,000,000 23.550 23,550,00023.7.2021 09:41:40 1,000,000 23.475 23,475,00023.7.2021 09:55:57 1.,000,000 23.475 23,475,000Total   10,000,000   238,600,000The trade is in accordance with Kvika’s buyback programme, announced on 16 July 2021 and...

The preliminary results for the second quarter of 2021 indicate that net earnings before tax will amount to ISK 3,550 – 3,650 million. TM’s combined ratio at a historical low and return on financial assets above expectations TM’s combined ratio was approximately 80.8% during the second quarter and 91.5% during the first half of 2021. The return on financial assets was 3.6% during the second quarter. TM’s net earnings before tax during the second quarter were approximately ISK 1,870 million. Solid growth in net fee and commission income and net interest income during the second quarter Net fee and commission income increased by roughly 20% between quarters and amounted to ISK 2,046 million during the second quarter, while net interest income amounted to ISK 1,156 million. Net investment income during the quarter amounted...